FDA warned California contract drug-testing lab Adamson over inadequate computer controls and data integrity failures.
What happened
FDA inspected Adamson Analytical Laboratories in Corona, California, from March 8 to 23, 2021. FDA found that the lab's gas and liquid chromatography systems lacked adequate controls over electronic data, including audit trails (records of who did what and when) that were not activated and analyst administrative privileges that allowed data deletion or alteration; it also found unvalidated electronic worksheets used for microbial testing. FDA called the computer-control issue a repeat violation from a 2016 warning letter and said the company's April 13, 2021, response was inadequate.
What FDA found
The lab did not adequately control its computer systems, allowing analysts to delete or change data and leaving audit trails off on chromatography instruments.
21 CFR 211.68(b)The lab used unvalidated electronic worksheets for microbial challenge testing, producing erroneous calculations.
21 CFR 211.68(b)The lab made critical changes to laboratory operations without review or approval by its quality group.
21 CFR 211.160(a)The lab activated instrument audit trails in February 2021 without governing procedures or change control.
21 CFR 211.160(a)The lab did not review audit trail data before releasing analytical results, though batch release data review requires it.
21 CFR 211.22The computer-control failure was a repeat violation from a 2016 warning letter, and promised corrections were not fully implemented.
21 CFR 211.68(b)
What FDA wants
FDA tells Adamson to correct the violations promptly and respond in writing within 15 working days with corrective actions, including lists of instruments and user privileges, an independent change-management assessment, and data-integrity remediation. FDA also strongly recommends a qualified consultant.
Who should pay attention
- drug manufacturers and brands that use this contract testing lab
- companies relying on Adamson's analytical or microbial test data for release
- quality teams managing contract laboratories and data integrity
This is a summary. Read the original letter on fda.gov.